According to Robert Simpson, Chairman-CEO of ATNG, "We are pleased to be
finalizing the purchase of Blue Kiwi. Blue Kiwi operations have been managed by
ATNG for several months, and Blue Kiwi has met the requirements for this
acquisition as determined by audit and is expected to be operating at a profit
within 90 days if unforeseen expenses are not incurred."

Blue Kiwi should enhance ATNG's gross profit. ATNG's progress to date is
measured by the substantial balance sheet improvements through debt reduction.
According to George Singer, President-CEO of Blue Kiwi, "We believe that Blue
Kiwi's aggressive media campaign scheduled to start in mid September will be
successful to the extent that it will strain our resources to produce Fatigue
Pack? and PMS Pack?. Initial customer response is very, very positive."

The purchase of Blue Kiwi includes all assets, trade secrets, trademarks,
intellectual property, etc. The Blue Kiwi product line is based on 12 years of
research related to the immune system managing growth of a bloodborne bacterium
in humans.

FENTON, Mich.--(BUSINESS WIRE)--Aug. 9, 2004--ATNG Inc. (OTCBB:ATNG) today
announced that it is again demanding an immediate delisting from the
Berlin-Bremen Stock Exchange in an attempt to prevent trading practices that
are banned in the United States. ATNG recently learned that it was one of
hundreds of companies added to the Berlin-Bremen Stock Exchange without its
knowledge, consent or authorization. ATNG's management has instructed its
counsel to request the immediate removal of ATNG's common stock from this
exchange. Requests by ATNG's counsel prior to this date have been ignored.

According to Robert Simpson, CEO of ATNG Inc., "We are taking legal action
against these illicit acts and as part of that legal action we are engaging a
German law firm. Additionally, we have no interest in trading on any exchange
on which we have not sought a listing."

ABOUT ATNG